Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Jan 5;135(1):11-19.
doi: 10.1097/CM9.0000000000001817.

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis

Ran Pan  1 , Xiaolun Wang  1 , Min Shu  1 , Jaydeep Das  2 , Manik Kalra  2 , Zhidong Wang  1
Affiliations
Meta-Analysis

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis

Ran Pan et al. Chin Med J (Engl). .

Abstract

Background: Psoriasis is a common, chronic, immune-mediated inflammatory skin disease with increased epidermal proliferation. The objective of this review was to systematically identify the evidence and perform a network meta-analysis (NMA) to estimate the relative efficacy of secukinumab (SEC) against adalimumab (ADA) and infliximab (INF) for the treatment of moderate-to-severe plaque psoriasis.

Methods: A systematic literature review (SLR) was conducted according to a pre-specified protocol to identify relevant studies. Initially, the databases were searched from database inception till June 2013, and the SLR was updated in April 2020. The eligibility criteria included adult patients (≥18 years old) with moderate-to-severe plaque psoriasis, and the SLR included randomized controlled trials (RCTs). The comparators of interest were SEC, ADA, INF, and placebo (PLA), while outcomes of interest were Psoriasis Area and Severity Index (PASI) (50, 75, and 90) at weeks 12, 16, and 24. A Bayesian NMA for PASI was utilized with a framework that evaluated the probability of PASI responses in different categories of PASI thresholds within a single model.

Results: A total of 23 RCTs that assessed the efficacy of SEC, ADA, and INF in patients with moderate-to-severe plaque psoriasis were identified. At 12 weeks, SEC was associated with a significantly better response compared with PLA and ADA for PASI 75 and 90, while response results were comparable against INF. At 12 weeks, risk ratio (95% confidence interval) derived from NMA for SEC vs. ADA and INF for PASI 75 was 1.35 (1.19, 1.57) and 1.01 (0.90, 1.18), respectively. At the 16-week and 24-week time interval, SEC was significantly better than PLA, ADA, and INF for PASI 75 and 90.

Conclusion: Efficacy of SEC in the treatment of patient populations with moderate-to-severe plaque psoriasis is well demonstrated through NMA.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Funnel plot of adalimumab vs. placebo.
Figure 2
Figure 2
Master network diagram for studies contributing for PASI outcome (base-case analysis). ADA: Adalimumab; ETA: Etanercept; GUS: Guselkumab; INF: Infliximab; MTX: Methotrexate; PASI: Psoriasis Area and Severity Index; PLA: Placebo; SEC: Secukinumab.
Figure 3
Figure 3
PASI response results for other treatment options vs. SEC 300 mg at 12 weeks. PASI: Psoriasis Area and Severity Index; RR: Risk ratio; SEC: Secukinumab.
Figure 4
Figure 4
Network diagram for studies contributing for PASI 100 at 12, 16, and 24 weeks. ADA: Adalimumab; ETA: Etanercept; GUS: Guselkumab; INF: Infliximab; MTX: Methotrexate; PASI: Psoriasis Area and Severity Index; PLA: Placebo; SEC: Secukinumab.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dogra S, Mahajan R. Psoriasis: epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J 2016; 7:471–480. doi: 10.4103/2229-5178.193906. - PMC - PubMed
    1. Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019; 20:1475.doi: 10.3390/ijms20061475. - PMC - PubMed
    1. Samarasekera EJ, Smith CH. National Institute of Health and Care Excellence; Royal College of Physicians. Psoriasis: guidance on assessment and referral. Clin Med (Lond) 2014; 14:178–182. doi: 10.7861/clinmedicine.14-2-178. - PMC - PubMed
    1. Chen XL, Zheng LY, Zhang H, Zhang JZ, Zhang CL, Ju M, et al. . Disease burden and quality of life in patients with psoriasis: an internet based questionnaire survey (in Chinese). Chin J Dermatol 2019; 52:791–795. doi: 10.35541/cjd.20190247.
    1. Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2018 complete edition) (in Chinese). Chin J Dermatol 2019; 52:667–710. doi: 10.35541/cjd.20190847.